Insider Trading Alert - REGN, MA, USB, LUV And AWAY Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Jan. 29, 2014, 48 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $2,167.07 to $320,146,398.72.

Highlighted Stocks Traded by Insiders:

Regeneron Pharmaceuticals (REGN) - FREE Research Report

Sanofi who is 10% Owner at Regeneron Pharmaceuticals bought 157,920 shares at $275.90 on Jan. 29, 2014. Following this transaction, the 10% Owner owned 16.0 million shares meaning that the stake was reduced by 1% with the 157,920-share transaction.

The shares most recently traded at $293.16, up $17.26, or 5.89% since the insider transaction. Historical insider transactions for Regeneron Pharmaceuticals go as follows:

  • 4-Week # shares sold: 4,000
  • 12-Week # shares sold: 13,000
  • 24-Week # shares sold: 19,000

The average volume for Regeneron Pharmaceuticals has been 835,900 shares per day over the past 30 days. Regeneron Pharmaceuticals has a market cap of $27.1 billion and is part of the health care sector and drugs industry. Shares are up 2.29% year-to-date as of the close of trading on Wednesday.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company has a P/E ratio of 39.0. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on REGN - FREE

TheStreet Quant Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company's earnings per share. Get the full Regeneron Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Regeneron Pharmaceuticals Ready to Make All-Time Highs

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

If It's Not Earnings News, It's Amazon Competition: Jim Cramer's Best Blog

Electronic Arts, Activision Blizzard and Take-Two Interactive: 'Mad Money' Lightning Round